Key facts
- This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 02 Jul 2024, 18:56.
Patrick Lamy - 28 Jun 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Signature
- /s/ Jonathan Young, Attorney-in-Fact
- Issuer symbol
- AKRO
- Transactions as of
- 28 Jun 2024
- Net transaction value
- +$4,407
- Form type
- 4
- Filing time
- 02 Jul 2024, 18:56:16 UTC
- Previous filing
- 13 Jun 2024
- Next filing
- 12 Dec 2024
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 02 Jul 2024.
Change
- Previous filing in this sequence was filed on 13 Jun 2024.
- Current net transaction value: +$4,407.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported transactions
AKRO
transaction
Common Stock
Award
- Transaction value
- $4,407
- Shares
- +221
- Change %
- +1.2%
- Price
- $19.94
- Shares after
- 18,783
- Date
- 28 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Mr. Lamy is voluntarily reporting the acquisition of these shares on June 28, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d). |
| F2 | In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on June 28, 2024. |